Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 1 min ago
Peer-reviewedCC BY-NC-NDHealth science reports

Skin‐Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real‐World Database Study (A Retrospective Cohort Study)

  • Akihito Hashizume1
  • Takashi Kawahara1
  • Masanobu Yamazaki1
  • Daiji Takamoto1
  • Teppei Takeshima1
  • Shinnosuke Kuroda1
  • Hiroji Uemura1
  • Kazuhide Makiyama2
  • Jun‐Ichi Teranishi1
  1. 1Yokohama City University Medical Center
  2. 2Yokohama City University
Read full textPDFCite

Related

  1. Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
    Daniel J. George, Jasmina I. Ivanova, Maëlys Touya +6
    Cancer medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
    Chi Kin Law, Martin R. Stockler, Andrew J. Martin +3
    EClinicalMedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  3. Real-World Early Prostate-Specific Antigen Response Comparison Among Patients with Metastatic Castration Sensitive Prostate Cancer Treated with Apalutamide or Abiraterone Acetate in the United States.
    Benjamin Lowentritt, Mehmet A Bilen, Sabree Burbage +6
    Journal of health economics and outcomes researchPeer-reviewedCC BYFull textOncologyEurope PMCPMC
  4. Perioperative apalutamide in high-risk localized or locally advanced prostate cancer: Is PROTEUS trial practice changing?
    Muhammed Huzaifa
    Indian journal of urology : IJU : journal of the Urological Society of IndiaPeer-reviewedCC BY-NC-SAFull textGeneral medicineEurope PMC
  5. Apalutamide-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient With Metastatic Prostate Cancer: A Case Report
    Shawly Kabir, Lynne Cormode
    CureusPeer-reviewedCC BYFull textOncologyPharmacology & toxicologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{hashizume2026skinrelated,
  title = {{Skin‐Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real‐World Database Study (A Retrospective Cohort Study)}},
  author = {Akihito Hashizume and Takashi Kawahara and Masanobu Yamazaki and Daiji Takamoto and Teppei Takeshima and Shinnosuke Kuroda and Hiroji Uemura and Kazuhide Makiyama and Jun‐Ichi Teranishi},
  journal = {Health science reports},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13659261},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Skin‐Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real‐World Database Study (A Retrospective Cohort Study)
AU  - Akihito Hashizume
AU  - Takashi Kawahara
AU  - Masanobu Yamazaki
AU  - Daiji Takamoto
AU  - Teppei Takeshima
AU  - Shinnosuke Kuroda
AU  - Hiroji Uemura
AU  - Kazuhide Makiyama
AU  - Jun‐Ichi Teranishi
PY  - 2026
DA  - 2026/10/01
JO  - Health science reports
UR  - https://europepmc.org/article/PMC/PMC13659261
SN  - 2398-8835
ER  -